SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-001112 to AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)

AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: Jan. 29, 2024 · CIK: 0001644963 · Accession: 0000000000-24-001112

AI Filing Summary & Sentiment

File numbers found in text: 333-276671

Date
January 29, 2024
Author
Not clearly detected
Form
UPLOAD
Company
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)

Letter

United States securities and exchange commission logo January 29, 2024 Alix MacLean Chief Executive Officer Avenue Therapeutics. Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Re:Avenue Therapeutics. Inc. Registration Statement on Form S-3 Filed on January 24, 2024 File No. 333-276671 Dear Alix MacLean: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rakesh Gopalan

Show Raw Text
United States securities and exchange commission logo
January 29, 2024
Alix MacLean
Chief Executive Officer
Avenue Therapeutics. Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
Re:Avenue Therapeutics. Inc.
Registration Statement on Form S-3
Filed on January 24, 2024
File No. 333-276671
Dear Alix MacLean:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Rakesh Gopalan